Peripherally Selective Mu Opioid Antagonists for Bowel Dysfunction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current opioid analgesics cause adverse gastrointestinal side effects like constipation, decreased gastric emptying, and bloating due to their action on peripheral opioid receptors, which are not effectively addressed by existing treatments without interfering with central analgesia.
Innovation Solution
Development of 3-carboxypropyl-aminotetralin compounds that act as selective mu opioid receptor antagonists, reducing gastrointestinal side effects while maintaining central analgesic effects, formulated into pharmaceutical compositions for administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If opioid analgesics are used to treat pain, then central analgesic effects are achieved, but gastrointestinal side effects worsen
Solution Approach 1:
The invention segments the opioid receptor system into central and peripheral components, using a peripherally selective antagonist (naloxegol) that specifically blocks peripheral mu-opioid receptors in the GI tract while allowing central analgesic effects to proceed unimpeded. This spatial segmentation resolves the contradiction by targeting only the harmful peripheral effects.
Solution Approach 2:
The peripherally selective antagonist acts as an intermediary agent that selectively blocks peripheral opioid receptors without interfering with central analgesia. This mediator substance enables differentiation between central therapeutic effects and peripheral side effects, resolving the contradiction through selective receptor antagonism.
2Productivity
If peripherally selective antagonist is used to block GI side effects, then gastrointestinal motility improves, but central analgesia may be affected
Solution Approach 1:
The antagonist exhibits local quality by being selectively distributed to and acting on peripheral opioid receptors in the gastrointestinal tract, while having minimal presence or effect in the central nervous system. This localized action improves GI motility without compromising central analgesia.
Solution Approach 2:
The drug's pharmacological action is segmented into peripheral and central domains, with the peripherally selective antagonist operating exclusively in the peripheral GI tract compartment. This segmentation ensures that gastrointestinal motility is improved while central analgesic effects remain intact.
3Reliability
If existing opioid treatments are used, then pain relief is achieved, but opioid-induced bowel dysfunction worsens
Solution Approach 1:
The peripherally selective antagonist serves as an intermediary substance that specifically counteracts the harmful bowel dysfunction effects of opioids by blocking peripheral mu-opioid receptors, while allowing the beneficial central pain relief effects to continue uninterrupted.
Solution Approach 2:
The invention converts the harmful peripheral opioid effects into a beneficial situation by using the same opioid analgesics for pain relief while simultaneously administering a peripherally selective antagonist that blocks only the harmful GI effects, thereby transforming the harmful contradiction into a beneficial dual-action therapy.
Data Source
AI summary
The invention provides 3-carboxypropyl-aminotetralin compounds of formula (I):wherein R1, R2, R3, R4, R5, and R6 are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.